Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: an in vitro study

Fertility and Sterility

Volumn 87, Issue 4, 2007, Pages 978-981

  Abdallah, Maher A ^a   Abdullah, Huda I ^b   Kang, Steven ^a   Taylor, Douglas D ^a   Nakajima, Steven T ^a   Gercel Taylor, Cicek ^a  

^a University of Louisville School of Medicine   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; EQUILIN; ESTRADIOL; GELATINASE A; GELATINASE B; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PROGESTERONE;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG MECHANISM; HORMONAL THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; EQUILIN; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEDROXYPROGESTERONE 17-ACETATE; NORETHINDRONE; PROGESTERONE;

EID: 34147135146     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.08.091     Document Type: Article

References (27)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 (1997) 1047-1059
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen and/or progestin in healthy postmenopausal women. Principal results from Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
3. Li C.I., Malone K.E., Porter P.L., Weiss N.S., Tang M.T., Cushing-Haugen K.C., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 (2002) 3254-3263
4. The Women's Health Initiative Steering Committee. Effects of conjugated estrogen on postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 291 (2004) 1701-1712
5. Visse R., and Nuguse H. Matrix metallorpoteinases and tissue inhibitor of metalloproteinases. Circ Res 92 (2003) 827-839
6. Sternlicht M.D., and Bergers G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerging Ther Targets 4 (2000) 609-633
7. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitor and cancer: trials and tribulations. Science 295 (2002) 2387-2392
8. Brown P.D., Bloxidge R.E., and Anderson F. Expression of activated gelatinase in human invasive breast carcinomas. Clin Exp Metastasis 11 (1993) 183-189
9. Bachmeier B.E., Albini A., Vene R., Beneli R., Noonan D., and Weigert C. Cell density dependent regulation of matrix metalloproteinases and TIMP expression in differentially tumorigenic breast cancer cell lines. Exp Cell Res 305 (2005) 83-98
10. Bazzett L.B., Magnus M., Taylor D.D., and Gercel-Taylor C. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. Gynecol Oncol 90 (2003) 435-442
11. Mueck A.O., Seeger H., and Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 6 (2003) 221-227
12. Stanzcyk F.Z. Estrogens used for replacement therapy in postmenopausal women. Gynecol Endocrinol 15 Suppl 4 (2001) 17-25
13. Maxson W.J., and Hergrove J.T. Bioavailability of oral micronized progesterone. Fertil Steril 44 (1985) 622-626
14. ® and Divina. A randomized, single blind, triple cross-over bioavailability study in menopausal women. Maturitas 18 (1994) 229
15. Stanczyk F.Z., Brzamer P.F., Mischell D.R., Ortiz A., Gentzchein E.E., and Guebelsmann L. A radioimmunoassay for norethindrone (NET). Measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 18 (1978) 615-633
16. Di Nezza L.A., Jobling T., and Salamonsen L.A. Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol Oncol 89 (2003) 325-333
17. Rodrik V., Zheng Y., Harrow F., Chen Y., and Foster D.A. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol 25 (2005) 7917-7925
18. Menendez J.A., Oza B.P., Colomer R., and Lupu R. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol 26 (2005) 1507-1515
19. Katzenellenbogen B.S. Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. J Soc Gynecol Invest 7 Suppl (2000) S33-S37
20. Sitruk-Ware R., and Plu-Bureau G. Exogenous progestogens and the human breast. Maturitas 49 (2004) 58-66
21. Sumida T., Itahana Y., Hamakawa H., and Desprez P. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form A or B of the progesterone receptor and then treatment with progestins. Cancer Res 64 (2004) 7886-7889
22. Skildum A., Faivre E., and Lange C.A. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19 (2005) 327-339
23. Luo X.H., and Liao E.Y. Progesterone differentially regulates the membrane-type matrix metalloproteinase-1 (MT1-MMP) compartment of proMMP-2 activation in MG-63 cells. Horm Metab Res 33 (2001) 383-388
24. Sounni N.E., Janssen M., Foidrit J.M., and Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in angiogenesis. Matrix Biol 22 (2003) 56-61
25. Leppa S., Saarto T., Vehmanen L., Blomquist C., and Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10 (2004) 1057-1063
26. Lippert T.H., Seeger H., and Mueck A. Pharmacology and toxicology of different estrogens. Gynecol Endocrinol 15 Suppl 4 (2001) 26-35
27. Archer D.F. Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. Semin Reprod Med 23 (2005) 188-195